肺癌患者基于网络的患者报告结局监测的成本效益
本研究基于法国一项多中心随机临床试验的数据,评估肺癌初始治疗后基于网络患者报告结局(PRO)监测相比常规监测的成本效益。PRO组人均年随访成本为941欧元,对照组为1304欧元,PRO组降低362欧元;增量成本效益比为每获得生命年12127欧元、每获得质量调整生命年(QALY)20912欧元。结论认为该监测方式节省随访成本,是具有成本效益的策略。
要点
- PRO组人均年随访成本941欧元,对照组1304欧元,PRO组降低362欧元。
- 增量成本效益比为每获得生命年12127欧元、每获得QALY 20912欧元。
- 该策略具有极高成本效益和成本效益的概率分别为97%和100%。
核心结论
- 基于网络PRO的肺癌患者监测降低了随访成本,相比常规监测是具有成本效益的策略,应考虑在肿瘤诊疗中应用。
研究设计与样本
- 本研究为基于法国多中心随机临床试验数据的医学经济学分析,并补充了病历摘要数据及咨询、影像、交通、信息技术和治疗成本。
主要发现
- PRO组人均年随访成本为941欧元,对照组为1304欧元,PRO组较对照组降低362欧元。
- 增量成本效益比为每获得生命年12127欧元、每获得QALY 20912欧元。
- 该策略具有极高成本效益的概率为97%,具有成本效益的概率为100%。
关键数值与推荐
- 意愿支付阈值采用每QALY 30000欧元定义为极具成本效益,每QALY 90000欧元定义为具有成本效益。
- 成本按法国实际报销费率计算,健康效用值基于科学文献综述估算。
- 增量成本效益比从健康保险支付方角度表达为每获得生命年和每获得QALY的成本。
临床怎么用
- 作者认为,基于网络PRO的监测相比常规监测是具有成本效益的策略,应考虑在肿瘤诊疗中应用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: A multicenter randomized clinical trial in France found an overall survival benefit of web-based patient-reported outcome (PRO)-based surveillance after initial treatment for lung cancer compared with conventional surveillance. The aim of this study was to assess the cost-effectiveness of this PRO-based surveillance in lung cancer patients. METHODS: This medico-economic analysis used data from the clinical trial, augmented by abstracted chart data and costs of consultations, imaging, transportations, information technology, and treatments. Costs were calculated based on actual reimbursement rates in France, and health utilities were estimated based on scientific literature review. Willingness-to-pay thresholds of €30,000 per quality-adjusted life year (QALY) and €90,000 per QALY were used to define a very cost-effective and cost-effective strategy, respectively. Average annual costs of experimental and control surveillance approaches were calculated. The incremental cost-effectiveness ratio was expressed as cost per life-year gained and QALY gained, from the health insurance payer perspective. One-way and multivariate probabilistic sensitivity analyses were performed. RESULTS: Average annual cost of surveillance follow-up was €362 lower per patient in the PRO arm (€941/year/patient) compared to control (€1,304/year/patient). The PRO approach presented an incremental cost-effectiveness ratio of €12,127 per life-year gained and €20,912 per QALY gained. The probabilities that the experimental strategy is very cost-effective and cost-effective were 97% and 100%, respectively. CONCLUSIONS: Surveillance of lung cancer patients using web-based PRO reduced the follow-up costs. Compared to conventional monitoring, this surveillance modality represents a cost-effective strategy and should be considered in cancer care delivery.
引用
- Lizée T, Basch E, Trémolières P, et al. Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung Cancer. J Thorac Oncol. 2019. PMID: 30776447. doi:10.1016/j.jtho.2019.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。